Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTAIR substudy 2: rilvegostomig with standard chemotherapy with or without ramucirumab in advanced or metastatic non-small cell lung cancer
CTR20262300Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rilvegostomig in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Dec 2025; status: active.
02
Drugs
rilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262300.